Latest Share Chat

PureTech Share News (PRTC)

PureTech Information

Buy PRTC Shares
Add PRTC to Watchlist
Add PRTC to Alert

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 214.00

Bid: 213.50

Ask: 214.50

Change: 0.00 (0.00%)

Spread: 1.00 (0.468%)

Open: 218.00

High: 218.00

Low: 213.50

Prev. Close: 214.00

Last checked at -

IN BRIEF: PureTech Health Investee Vor Biopharma Prices US IPO

Fri, 05th Feb 2021 14:00

PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - Says founded entity Vor Biopharma has priced its initial public offering of 9.8 million shares at USD18.00 per share, resulting in gross proceeds of USD176.9 million. Notes Vor Biopharma filed for an IPO with the US Securities & Exchange Commission in January. Says shares to trade on the Nasdaq Global Market, with the offering expected to close next Tuesday. Goldman Sachs & Co LLC, Evercore ISI, Barclays and Stifel are acting as book runners for the offering. PureTech owns 3.2 million Vor shares, giving it a 9.0% stake following the IPO.

Current stock price: 369.50 pence

Year-to-date change: down 7.6%

By Zoe Wickens; zoewickens@alliancenews.com

More News

5 Sep 2022 11:40

IN BRIEF: PureTech Health data on fibrosis drug candidate positive

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Posts positive data from a phase 1 trial of its idiopathic pulmonary fibrosis drug candidate LYT-100, or deupirfenidone.

31 Aug 2022 20:31

TOP NEWS: ConvaTec to join FTSE 100 as abrdn vacates spot

(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, September 19 after completing its quarterly review.

25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

25 Aug 2022 11:03

SMALL-CAP WINNERS & LOSERS: Hunting surges as loss narrows, ups payout

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

25 Aug 2022 10:10

IN BRIEF: PureTech Health loss narrows in "exceedingly strong" half

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Pretax loss in the first half 2022 narrows to USD56.0 million from USD94.9 million a year before. This is due to a USD28.4 million gain on the dilution of its equity interest in Gelesis Inc. Revenue grows 21% to USD7.0 million from USD5.8 million. Attributes this to increased grant revenue from the Vedanta CARB-X and BARDA grant, as well as Alivio and PureTech LYT Inc.

25 Aug 2022 09:25

PureTech first-half mixed as it makes good clinical progress

(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.

24 Aug 2022 17:58

IN BRIEF: PureTech Health's Sonde Health signs deal for COPD in India

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says its founded entity, Sonde Health, has signed a multi-year agreement with specialty pharmaceutical company Koye Pharmaceuticals Pvt Ltd. The agreement is to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This is Sonde's first partnership with a pharmaceutical firm, PureTech adds.

23 Aug 2022 18:14

TOP NEWS: abrdn indicated to drop out of FTSE 100, F&C to join

(Alliance News) - Almost 18 months after announcing a name change, abrdn PLC's blue-chip status is under threat, according to indicative index changes provided by FTSE Russell on Tuesday.

22 Aug 2022 09:15

PureTech Health's Akili raises USD163 million via Nasdaq IPO

(Alliance News) - PureTech Health PLC said founded entity Akili Inc will start trading on the Nasdaq Capital Market on Monday, after raising funds which will go towards video-game based treatment for children.

9 Aug 2022 09:31

PureTech gets USD115 million from sale of Karuna Therapeutics shares

(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc.

8 Aug 2022 17:06

LONDON MARKET CLOSE: Strong start to week as US inflation data looms

(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.

8 Aug 2022 16:21

IN BRIEF: PureTech shares jump on Karuna Therapeutics trial results

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.

1 Aug 2022 21:21

IN BRIEF: PureTech Health's Aliki starts phase three study for SDT-001

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.

11 Jul 2022 19:15

TRADING UPDATES: BlueRock hit by extreme weather; Harbour drills well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

30 Jun 2022 21:50

IN BRIEF: PureTech Health begins pulmonary fibrosis study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Begins late-stage clinical study of its wholly-owned candidate LYT-100, or deupirfenidone, in idiopathic pulmonary fibrosis. Will evaluate efficacy of two doses, as well as relative tolerability and efficacy with pirfenidone. IPF is a chronic condition causing progressive scarring of the lungs, which currently has a poor prognosis. Also advances LYT-200 programme through clinical development, and plans to begin leukemia study by the end of 2022.

Latest Share Chat

PureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: PureTech Health Investee Vor Biopharma Prices US IPO

Login to your account

Quickpicks are a member only feature

Login to your account